Prostate cancer Posts - Page 2 of 76 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Posted by on Sep 19, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed whether robot-assisted radical prostatectomy (RARP) improves lower urinary tract symptoms (LUTS) and quality of life (QoL) in patients with prostate cancer (PCa). The data showed an improvement in LUTS and QoL in patients with previously moderate or severe LUTS, 12 months after RARP. Some background PCa...

Read More

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Sep 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...

Read More

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function. Some background CRPC is prostate cancer that keeps growing...

Read More

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Read More

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared 2 approaches of robot-assisted radical prostatectomy (RARP) for the treatment of localized prostate cancer (PCa). The authors concluded that both transvesical (T) and posterior (P) approaches had similar results in these patients. Some background Localized prostate cancer (PCa) is cancer that is...

Read More

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More

Comparing the overall survival rates to general life expectancy predictions after radical prostatectomy in patients with prostate cancer.

Comparing the overall survival rates to general life expectancy predictions after radical prostatectomy in patients with prostate cancer.

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the overall survival rates to general life expectancy predictions after radical prostatectomy (RP; prostate removal surgery) in German patients with localized prostate cancer. The study found that low- and intermediate-risk patients treated with RP have increased overall survival rates compared to general life...

Read More

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher...

Read More

Is age associated with a poorer outcome for patients undergoing delayed prostate surgery following active surveillance?

Is age associated with a poorer outcome for patients undergoing delayed prostate surgery following active surveillance?

Posted by on Aug 8, 2021 in Prostate cancer | 0 comments

In a nutshell This study looked at whether age is related to a risk of poor outcomes in men undergoing delayed radical prostatectomy (RP; prostate removal surgery) following active surveillance (AS). The authors found that older patients require closer monitoring when on AS and may require additional testing to identify the progression of their...

Read More

Reducing unnecessary blood tests after robot assisted prostate surgery

Reducing unnecessary blood tests after robot assisted prostate surgery

Posted by on Aug 8, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety of eliminating routine postoperative blood tests after conducting robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer (PCa) and proposed recommendations for their use.  Some background Localized prostate cancer (PCa) refers to cancer that is confined to the prostate...

Read More

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More